Riparian Pharmaceuticals Overview
- Year Founded
-
2012
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
Riparian Pharmaceuticals General Information
Description
Developer of pathophysiology therapeutics designed to improve endothelial function to reduce vascular complications. The company's therapeutics target new vasoprotective pathways to treat both prevalent and serious rare vascular diseases early, enabling physicians to have improved patient outcomes.
Contact Information
Website
www.riparianpharma.comCorporate Office
- 201 Dexter Avenue
- Watertown, MA 02472
- United States
Corporate Office
- 201 Dexter Avenue
- Watertown, MA 02472
- United States
Riparian Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Out of Business | 01-Jun-2026 | Completed | Out of Business | |||
| 9. Grant | 01-May-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A2) | 01-Apr-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series A1) | 12-Oct-2018 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 05-Oct-2017 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 13-Oct-2016 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | Completed | Startup | ||||
| 3. Grant | 06-Jun-2016 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2016 | $2.83M | Completed | Generating Revenue | ||
| 1. Grant | 01-Jan-2013 | $857K | Completed | Startup |
Riparian Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Riparian Pharmaceuticals Patents
Riparian Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025032440-A1 | Klf2 inducing compounds and uses thereof | Inactive | 04-Aug-2023 | ||
| US-20250109143-A1 | Klf2 inducing deuterated compounds and uses thereof | Pending | 04-Aug-2023 | ||
| AU-2023216716-A1 | Inducers of klf2 and methods of use thereof | Inactive | 07-Feb-2022 | ||
| EP-4476229-A1 | Inducers of klf2 and methods of use thereof | Pending | 07-Feb-2022 | ||
| EP-4476229-A4 | Inducers of klf2 and methods of use thereof | Pending | 07-Feb-2022 | C07D498/04 |
Riparian Pharmaceuticals Signals
Riparian Pharmaceuticals FAQs
-
When was Riparian Pharmaceuticals founded?
Riparian Pharmaceuticals was founded in 2012.
-
Where is Riparian Pharmaceuticals headquartered?
Riparian Pharmaceuticals is headquartered in Watertown, MA.
-
What is the size of Riparian Pharmaceuticals?
Riparian Pharmaceuticals has 2 total employees.
-
What industry is Riparian Pharmaceuticals in?
Riparian Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Riparian Pharmaceuticals a private or public company?
Riparian Pharmaceuticals is a Private company.
-
What is Riparian Pharmaceuticals’s current revenue?
The current revenue for Riparian Pharmaceuticals is .
-
How much funding has Riparian Pharmaceuticals raised over time?
Riparian Pharmaceuticals has raised $6M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process